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AbstrACt
Introduction Published in 2018, the 5C scale is 
psychometrically validated to assess five psychological 
antecedents of vaccination (confidence, complacency, 
constraints, calculation and collective responsibility). The 
original version offers a validated English and German 
scale to assess these determinants with a short 5- item 
scale (1 item per antecedent) and a long 15- item scale (3 
items per antecedent). This sample study protocol provides 
a step- by- step guidance for the process of adapting the 
5C scale to another country, language or cultural context. 
Data obtained from the 5C scale can support developing, 
implementing and evaluating an intervention and 
monitoring of general vaccine acceptance and demand.
Methods and analysis Phase 1 comprises the adaptation 
of the 5C scale including the translation and back 
translation of the antecedents, an expert evaluation of the 
antecedents and the identification of new antecedents as 
well as a pretest. Phase 2 involves the validation of the 
translated and potentially expanded scale including the 
assessment of reliability, construct and concurrent validity 
of all items of the scale. Code for data analysis is provided.
Ethics and dissemination The University of Erfurt’s 
institutional review board provided ethical clearance 
(EV-201900416.2). The authors suggest and encourage 
publicly sharing all data obtained from the translated 5C 
scale (eg, on publication). The materials and the code for 
data analysis to support the process described in this 
protocol are available in https:// osf. io/ 2agxe/. Sharing data 
on vaccine acceptance and demand is in the public and 
the scientific interest and will facilitate gaining a global 
overview of its current state and development over time. 
The authors of the original 5C scale are currently working 
on an online platform to facilitate publishing the data and 
to visualise the psychological antecedents across different 
countries.
IntroduCtIon
Since vaccine hesitancy has been identified 
as a global challenge,1 scientists and profes-
sionals have made many attempts to develop 
metrics (typically understood as a question-
naire or scale, we will henceforth refer to this 
as scales see box 1) to quantitatively assess why 
individuals avoid vaccination even though 
safe and effective vaccines are available (for 
an overview of the scales, see Betsch et al2). 
Betsch and colleagues have recently proposed 
measuring five psychological antecedents 
of vaccination that synthesise and extend 
prior models of vaccine hesitancy and confi-
dence.3–5 Antecedents are psychological 
reasons or determinants within a person (eg, 
a parent) that are related to whether or not 
a person vaccinates. The five antecedents are 
confidence, complacency, constraints, calcu-
lation and collective responsibility (detailed 
definitions below). The 5C scale assesses five 
psychological antecedents of vaccination and 
provides insights into the individual mental 
representations, attitudinal and behavioural 
tendencies that are a result of the environ-
ment and context the respondent lives in. 
For example, perceived constraints could be 
a function of a lack of access, inappropriate 
service delivery or, for minority groups, a 
reluctance to get registered.2 In sum, the 
antecedents are related to how someone 
strengths and limitations of this study
 ► Adaptation and validation of the existing 5C scale 
increase comparability across countries, contexts 
and languages.
 ► Validation of translated and adapted scales ensures 
that the scales measure the intended constructs.
 ► Openly available materials support the adaptation 
and validation process.
 ► The availability of validated scales allow countries to 
monitor and detect potential early warning signals 
of vaccine hesitancy and support evidence- based 
intervention design.
 ► The suggested process needs expertise from differ-
ent fields and can be time- consuming.
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box 1 Glossary
Antecedent: Reason or determinant that is related to vaccination be-
haviour (eg, confidence)
Concurrent validity: Indicates whether an antecedent predicts a vac-
cination behaviour or intention, as assessed simultaneously with the 
antecedent.
Construct: A theoretical, not directly observable, entity measured by 
several items; the antecedents of vaccination are also constructs.
Construct validity: Quality indicator that ensures that a scale mea-
sures what it aims to assess; usually assessed as correlations between 
constructs.
Item: Single question in a questionnaire; several items are used to mea-
sure one theoretical construct or antecedent.
reliability: Quality indicator that indicates the scale’s internal consis-
tency, usually assessed as a Cronbach’s alpha value.
scale: Set of items (questions) to measure a construct (eg, antecedents 
of vaccination); synonyms are metrics, measure, tool, questionnaire.
subscale: Subset of items; within a scale, there can be several sub- 
scales (eg, the 5C scale has five subscales, each measuring one 
antecedent).
Validation construct: To establish construct validity (Does a scale 
measures what it aims to measure?), validation constructs are correlat-
ed with the scale. Based on theories or prior findings there are hypothe-
ses regarding the nature of the correlation (eg, if the confidence scales 
measures what it intends to measure, it should be positively correlated 
with the validation constructs attitudes, trust in health systems and the 
effectiveness of vaccines).
thinks and feels about vaccination and being vaccinated. 
They influence vaccination behaviour to varying degrees, 
depending on the specific vaccination and the setting 
where the scale is used.
The original version of the 5C scale offers a validated 
English and German scale to assess these antecedents with 
a short 5- item scale (1 item per antecedent; an item is a 
question in a questionnaire) and a long 15- item scale (3 
items per antecedent; find all items in table 1). The items 
look at vaccination in general (as opposed to one specific 
vaccine, or childhood vaccines). Analyses showed that the 
general versus a specific wording of the 5C scale items 
work similarly well. When the 5C scale builds the basis 
of an intervention, for example, for a measles vaccine 
campaign, it is, however, recommended to change the 
wording of the items to make them vaccine- specific (eg, 
asking for people’s confidence in the measles vaccine).2
Studies comparing the performance of several similar 
scales showed that, overall, the 5C scale outperformed 
other scales in the amount of explained variance of self- 
reported vaccination behaviour.2 This may especially be 
the case because most of the existing scales assess only 
vaccine confidence, that is, the trust in the safety and 
effectiveness of vaccines and trust in healthcare providers 
or systems.2 The 5C scale captures a broader range of 
antecedents such as constraints, while at the same time 
providing the possibility to assess them in a short and 
economic way. Therefore, the 5C scale is a valid, effective 
and economic tool to assess the psychological anteced-
ents of vaccination.
The availability of validated scales of vaccine hesitancy/
confidence and their regular use in a country allow moni-
toring the antecedents of vaccination and detecting poten-
tial early warning signals.6 Repeated assessments could 
show declining confidence or increasing constraints, for 
example. This information will allow designing specific 
interventions that can address particular challenges.5 
Thus, identifying underlying causes and problems is 
linked to potential solutions. Moreover, assessments of 
the 5C scale in specific target groups (eg, the elderly) and 
comparisons of fully and undervaccinated subpopulations 
can identify the antecedents that contribute to vaccine 
uptake.7 Campaigns or targeted interventions can aim at 
changing these particular antecedents, with the goal of 
an overall increase in vaccination. For example, using the 
5C scale in a model region in Germany suggested that the 
elderly were undervaccinated due to their lack of confi-
dence and high complacency.7 A specifically designed 
intervention (with inputs from design, communication 
science, medicine and epidemiology) addressed these 
particular antecedents and increased the self- reported 
vaccine uptake in the subsequent year.8 The 5C scale can 
also be a useful evaluation tool by (a) measuring the 5C 
antecedents before and after an intervention and (b) 
comparing the 5C scores of individuals who were either 
aware or unaware of the prior campaign.
5C antecedents of vaccination
In this section, we describe the 5C antecedents of vaccina-
tion and report the results and the quality indicators from 
previous validation studies, that is, information about the 
subscales’ reliability (a subscale measures one antecedent 
with several items), as well as information about their 
construct and concurrent validity:
 ► Reliability, usually assessed by Cronbach’s alpha, indi-
cates the scale’s internal consistency, that is, the mean 
item intercorrelation (provided in table 1).
 ► Construct validity refers to the fact that a scale meas-
ures what it aims to assess (eg, Does a scale measuring 
confidence indeed measure confidence in vaccines as 
it is defined?). This is assessed by correlating the ante-
cedent with similar constructs. For example, the atti-
tude toward vaccination is similar to but not the same 
as confidence in vaccines and should thus positively 
correlate with confidence. Table 2 suggests constructs 
that can be used for validation. Previous studies have 
already assessed the antecedents’ correlations with 
similar validation constructs.2 These results are also 
provided in table 2 to provide a benchmark.
 ► Concurrent validity indicates whether an antecedent 
predicts a vaccination behaviour or intention, as 
assessed simultaneously with the antecedent (eg, 
confidence is significantly related to whether a person 
has been vaccinated against the influenza2).
The first antecedent is confidence, defined as “trust in (i) 
the effectiveness and safety of vaccines, (ii) the system that 
delivers them, including the reliability and competence 
of the health services and health professionals, and (iii) 
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Table 1 5C definitions with original English and German items, to assess the psychological antecedents of vaccination2
Definitions of 5C 5C (US)—English version of 5C items 5C (DE)—German version of 5C items
Confidence α=0.85
“trust in (i) the effectiveness and safety of 
vaccines, (ii) the system that delivers them, 
including the reliability and competence of 
the health services and health professionals, 
and (iii) the motivations of policy- makers who 
decide on the need of vaccines”3 (p4162)
I am completely confident that vaccines are 
safe.
Ich habe vollstes Vertrauen in die Sicherheit 
von Impfungen.
Vaccinations are effective. Impfungen sind effektiv.
Regarding vaccines, I am confident that public 
authorities decide in the best interest of the 
community.
Was Impfen anbelangt, vertraue ich darauf, 
dass staatliche Behörden immer im besten 
Interesse für die Allgemeinheit entscheiden.
Complacency α=0.76
“perceived risks of vaccine- preventable 
diseases are low and vaccination is not 
deemed a necessary preventive action”3 
(p4162)
Vaccination is unnecessary because 
vaccine- preventable diseases are not 
common anymore.
Impfungen sind überflüssig, da Krankheiten, 
gegen die man sich impfen lassen kann, 
kaum noch auftreten.
My immune system is so strong; it also 
protects me against diseases.
Mein Immunsystem ist so stark, es schützt 
mich auch vor Erkrankungen.
Vaccine- preventable diseases are not so 
severe that I should be vaccinated.
Krankheiten, gegen die man sich impfen lassen 
kann, sind nicht so schlimm, dass ich mich 
gegen sie impfen lassen müsste.
Constraints α=0.85
“physical availability, affordability and 
willingness- to- pay, geographical accessibility, 
ability to understand (language and health 
literacy) and appeal of immunization service 
affect uptake”3 (p4163)
Everyday stress prevents me from being 
vaccinated.
Alltagsstress hält mich davon ab, mich 
impfen zu lassen.
For me, it is inconvenient to be vaccinated. Es ist für mich aufwändig, eine Impfung zu 
erhalten.
Visiting the doctor makes me feel 
uncomfortable; this keeps me from being 
vaccinated.
Mein Unwohlsein bei Arztbesuchen hält mich 
vom Impfen ab.
Calculation α=0.78
individuals’ engagement in extensive 
information searching; deliberate comparison 
of the risks of infections and vaccination from 
which to derive an informed decision2
When I think about being vaccinated, I 
weigh its benefits and risks to make the 
best decision possible.
Wenn ich daran denke, mich impfen zu 
lassen, wäge ich Nutzen und Risiken ab, um 
die bestmögliche Entscheidung zu treffen.
For each and every vaccination, I closely 
consider whether it is useful for me.
Ich überlege für jede Impfung sehr genau, ob 
sie sinnvoll für mich ist.
It is important for me to fully understand the 
topic of vaccination before I get vaccinated.
Ein volles Verständnis über die Thematik der 
Impfung ist mir wichtig, bevor ich mich impfen 
lasse.
Collective responsibility α=0.71
“willingness to protect others by one’s own 
vaccination by means of herd immunity (flip 
side: willingness to have a free ride when 
a sufficient number of other people are 
vaccinated)”2 (p7).
When everyone else is vaccinated, I don’t 
have to be vaccinated, too. (R)
Wenn alle geimpft sind, brauche ich mich 
nicht auch noch impfen zu lassen. (R)
I get vaccinated because I can also protect 
people with a weaker immune system.
Ich lasse mich impfen, weil ich auch Menschen 
mit einem schwachen Immunsystem schützen 
kann.
Vaccination is a collective action to prevent the 
spread of diseases.
Impfen ist eine gemeinschaftliche Maßnahme, 
um die Verbreitung von Krankheiten zu 
verhindern.
Instruction for the 5C scale: “Please evaluate how much you disagree or agree with the following statements.” (1=strongly disagree, 2=moderately 
disagree, 3=slightly disagree, 4=neutral (or: neither disagree nor agree), 5=slightly agree, 6=moderately agree, 7=strongly agree). Scoring: mean 
score across items per antecedent. Each item with (R) is reverse- coded. The items used for the short scale are in bold font. Cronbach’s α refers to 
the English version (as published in Betsch et al2). The German translation of the collective responsibility scale has not yet been tested in a German 
sample.
5C, scale to assess five psychological antecedents of vaccination.
the motivations of policy- makers who decide on the need 
of vaccines”3 (p2). Studies have revealed that individuals 
who lack confidence have negative attitudes toward vacci-
nation (table 2); lower confidence is also related to more 
misinformation, the belief in conspiracies, doubts about 
the benefits of medicine and mistrust in the healthcare 
system.2
Complacency “exists where perceived risks of vaccine- 
preventable diseases are low and vaccination is not 
deemed a necessary preventive action”3 (p2). In correla-
tional analyses (table 2), higher complacency is related 
to the perceived lower risk of a disease and when vaccina-
tion is not perceived a social norm. Higher complacency 
is related to a greater interest in immediate outcomes 
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Table 2 Suggested validation constructs for phase 2
Antecedents Suggested validation constructs for the respective antecedents
Previous correlations between 
the mean ‘C’ (three items) and 
validation constructs2
Confidence Attitude toward vaccination is defined as the degree to which the 
performance of the behaviour is positively or negatively valued (eg, 
“Vaccination is necessary.”)19.
0.78
  Vaccination knowledge is defined as a set of items that reflects common 
misconceptions about vaccinations in general, including ‘questions about 
the immunisation process related to vaccination, the impact of vaccination 
and the consequences of vaccination’ (eg, “The efficacy of vaccines has 
been proven.”)20.
0.47
  Trust in the healthcare provider is defined as how patients perceive 
healthcare providers in terms of their competence, honesty, maintaining 
confidentiality and fidelity/agency (eg, “My healthcare provider is usually 
considerate of my needs and puts them first.”)21.
0.46
  Trust in healthcare institutions (eg, “Healthcare institutions provide the 
highest quality of medical care.”)21.
0.32
Complacency Perceived risk of a disease, one item (eg, “Suppose that you do not have 
measles—vaccination and that you are not yet suffering from measles. 
How high do you estimate the likelihood of contracting measles in your 
lifetime?”)
−0.28
  Invulnerability is defined as a felt sense of invulnerability to injury, harm and 
danger (eg, “I’m unlikely to be hurt if I do a dangerous thing.”)22.
0.47
Constraints Perceived behavioural control is defined as individual control beliefs 
regarding the performance of a behaviour, such as the perceived ease 
or difficulty of being vaccinated (eg, “It is mostly up to me whether I get 
vaccinated.”)17.
Not yet determined, expected: 
negative correlation
  Perceived access to healthcare is defined as the individually perceived 
likelihood of accessing the necessary healthcare (“Please report the 
likelihood of accessing healthcare if you should need it over the next 12 
months.”)23.
−0.17
Calculation Preference for deliberation is defined as a reflective, cognition- based mode 
(beliefs, evaluations and reasons) (eg, “I prefer making detailed plans rather 
than leaving things to chance.”)24 25.
0.30
  Conscientiousness is defined as an individual’s inclination to be organised, 
productive and responsible (eg, “I am someone who is reliable and can 
always be counted on.”)26.
Not yet determined; expected: 
positive correlation
Collective 
responsibility
Communal orientation is defined as the desire or feeling obligated to 
benefit another person in need (eg, “I often go out of my way to help 
another person.”) or it refers to expectations of reciprocity27.
0.35*
  Empathy is defined as an individual’s emotional reaction (eg, compassion) 
to another’s emotion (eg, sadness)28 (eg, “I have a strong urge to help when 
I see someone who is upset.”).
0.37*
Validation constructs are expected to be meaningfully correlated with the respective 5C construct. The items for the suggested validation 
constructs are provided (in English) in https://osf.io/2agxe/
*Denotes the correlation with the one- item version.
5C, scale to assess five psychological antecedents of vaccination.
(than future ones) and to more risk- seeking behaviour. 
Individuals with high complacency indicate higher feel-
ings of invulnerability than those with low complacency.2
Constraints are structural or psychological barriers (eg, 
lack of or limited (perceived) access, lack of self- control) 
to the conversion of vaccination intentions into actual 
behaviour. The correlations (table 2) show that higher 
scores on the constraints variable are negatively related to 
perceived behavioural control, self- efficacy and perceived 
access to healthcare. Perceived higher constraints are also 
positively related to the feelings of being under time pres-
sure and being overwhelmed with daily challenges.2
Calculation refers to individuals’ engagement in exten-
sive information searching and indicates a deliberate 
comparison of the risks of infections and vaccination 
from which to derive an informed decision. As shown 
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in the correlational analyses (table 2), individuals who 
score high in calculation are risk averse, perceive higher 
risks related to vaccination and have a more deliberative 
cognitive style of decision- making. However, calculation 
is not associated with a better ability to understand or use 
numbers (numeracy).2
Collective responsibility is defined as “the willingness to 
protect others by one’s own vaccination by means of herd 
immunity. The flipside is the willingness to have a free 
ride when a sufficient number of other people are vacci-
nated”2 (p7). In the validation studies, high collective 
responsibility was positively correlated with collectivism, 
communal orientation and empathy (table 2).2
objECtIVEs
To make the benefits of the tool available to a broader 
range of countries, this sample study protocol aims to 
provide a step- by- step support for translating, adapting 
and validating the 5C scale in another country, language 
or cultural context. Thus, when the scale is intended to 
be used in a setting other than Germany or the USA, 
where previous validation studies have been conducted, 
it is strongly advisable to first, translate the items into the 
local language. Second, it should be critically evaluated 
whether all relevant antecedents are covered by the scale 
or whether it needs adaptation. Other cultural settings 
may make it necessary to include other antecedents, such 
as compatibility with religious beliefs, the existence of 
other traditional ways of healing, the role of particular 
social influence (eg, strong influence by husbands on the 
vaccination decision) or other factors. Third, it will be 
necessary to conduct a new validation, that is, to correlate 
the 5C antecedents with the validation constructs. This 
method will ensure that the translated items will measure 
the antecedents as defined.
Following the same study protocol allows better compa-
rability of the data obtained from the scale when used 
in different countries, contexts and languages—even if 
slight changes in the wording of the items are necessary 
or when new context- specific antecedents are added to 
the scale. The remainder will provide detailed method-
ological and statistical support for this process.
MEthods And AnAlysIs
This protocol suggests a study with two phases. Figure 1 
provides an overview of the phases and steps, and table 3 
provides a checklist for the process and gives an overview 
of the materials needed in each step. Phase 1 translates the 
existing items and assesses whether adaptation is needed, 
that is, whether it needs to be extended. Phase 2 adds a 
protocol for the validation of the translated version and 
of newly added antecedents including the description of 
the study design and an estimation of how many partici-
pants will be needed.
We share materials mentioned in table 3 (eg, translation 
tables, data legend, syntax for data analysis) to support the 
process described in this protocol via the Open Science 
Framework (OSF; see https:// osf. io/ 2agxe/), a ‘free 
and open- source project management repository that 
supports researchers across their entire project life cycle’ 
(cited from the website9). We encourage other scientists 
to ‘fork’ the OSF component and make their data and 
materials available to other scientists in the new fork. 
Forking means creating ‘a copy of an existing project 
and its components. The fork always points back to the 
original project, forming a network of citations’ (from 
the website10). In this way, an international open network 
of vaccine acceptance and demand research can emerge, 
making global monitoring possible. The authors of the 
original 5C scale are currently working on an online plat-
form to share the data and visualise the psychological 
antecedents across different countries.
Phase 1: translation and adaptation
The objective of phase 1 is to assess whether the first 
translation of the 5C items covers the definitions of the 
antecedents. Moreover, it aims to assess which anteced-
ents need to be added beyond the 5C and to generate a 
set of items for the potential new antecedent(s).
Translation of the existing items
In the beginning of the process, it is necessary to trans-
late the original items into the target language. It is 
recommended that the translation be made by at least 
two independent translators: Person A translates 5C from 
English/German into the new language, Person B back- 
translates the items into English/German. The research 
team should then compare the original items with the 
back- translated items and identify where items or words 
seems to differ. Person A and B should then develop an 
agreed- on version based on the comments, the original 
items and the translated items. In some cases, it can be 
useful to consult a linguist.
Expert evaluation
Next, it should be critically examined whether the 
agreed- on translation covers the concepts as defined. 
Thus, experts should rigorously evaluate the existing 
translated items vis-à-vis the definitions of the antecedents 
(eg, as provided in table 1). The experts may be stake-
holders, such as policy- makers, other researchers (from 
social and behavioural sciences and epidemiology), EPI 
(Expanded Programme on Immunisation) managers, 
clinic managers, funders, healthcare providers, parent or 
patient organisations. We suggest that researchers who 
undertake the translation and the adaptation hold either 
a stakeholder workshop or conduct focus group discus-
sions to gain these experts’ feedback on the translated 5C 
items, inviting discussions on where the antecedents and 
associated items should be extended to comprehensively 
capture vaccine acceptance, demand and behaviour.
In general, we advise that the original 5C items should 
not be changed substantially with respect to the wording 
of the items as this limits comparability of the results at 
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Figure 1 From 5C to 5C+(COUNTRY). In naming the resulting scale, we suggest adding the country in parentheses, in 
which the validation took place (eg, 5C (DE) or 5C (US)) and a ‘+’ sign when an antecedent is added. 5C, scale to assess five 
psychological antecedents ofvaccination; 5C+(COUNTRY), extended scale to assess more than five psychological antecedents 
of vaccination, translated in the language of a certain country (given in parentheses).
later stages. If needed, the set of items can be extended 
by adding new items that cover additional facets of an 
antecedent. For example, in case of a preconception 
that a service delivery may pose a problem, the stake-
holders may wish to add an item to assess the antecedent 
‘constraints’ that pertains more explicitly to this aspect 
(eg, ‘The way in which vaccines are offered keeps me 
from being vaccinated’.).
Identifying new antecedents
Based on the stakeholder workshop or the focus group 
discussions, the antecedents of the existing 5C scale may 
be extended. For each of the newly identified antecedent, 
the researchers and the stakeholders should agree on a 
clear definition. This is important to build the founda-
tion for the item generation, as well as to select the vali-
dation constructs. It is important to note that vaccination 
is a very complex topic and there is a plethora of possible 
reasons why people vaccinate or do not vaccinate. No 
scale will ever be able to capture every single reason—and 
lots of reasons may be summarised under one conceptual 
umbrella (eg, positive attitudes toward vaccination and 
trust in the system under the umbrella of confidence). 
The challenge with this process is to find distinct anteced-
ents (umbrellas, to stay with this metaphor) that add 
unique information and to group items that capture 
different behaviours or reasons under the same umbrella.
The amount of antecedents and items should be 
balanced with respect to costs and efforts for scale valida-
tion. When adding a new antecedent, we recommend to 
generate items that reflect a great variety of possible facets 
of the respective antecedent. A minimum of 6 to 10 items 
should then be formulated for each new antecedent to 
undergo pretesting and validation (phase 2). We recom-
mend following the principles of good item generation 
(for overviews, see, eg, table 1 in Simms11 or table 1 in 
Tsand et al12). The goal is to develop a new subscale that 
covers the antecedent well; therefore, at least three valid 
and reliable items should be selected in the validation 
process (phase 2) to match the three- item- per- antecedent 
structure of the original scale.2
Pretest
Small- scale qualitative pretesting of the resulting items 
should be conducted to ensure their comprehensibility 
before conducting phase 2. This applies both when new 
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Table 3 Checklist for translating, adapting and validating the 5C scale and overview of supporting materials
Phase 1. Translation and adaptation Documents in OSF to support the process
Translation and back- translation of all items. Translation tables
Identify whether the items capture the definitions of their respective 
antecedents (discussions, face validity).
Slides for a workshop
Draft additional items for the existing 5C scale if necessary.   
Identify new antecedents and draft new items. Draft topic guide for a focus group discussion; 
slides for a workshop
Qualitative pretest: cognitive interviews with n=5–10 people to clarify 
whether the questions are easy to understand.
Instructions for the cognitive interviews
Phase 2. Validation of the translated 5C scale (5C+(COUNTRY))*   
Validation study involving n=300+ participants, a heterogeneous 
convenience sample.
Use the suggested validation constructs, and, if new antecedents were 
added, add items to validate that new antecedent.
Aims:
 ► Assess the reliability of the 5C+ antecedents. Do all items belonging 
to one antecedent relate to each other, indicating that they indeed 
measure the same antecedent?
 ► Assess construct validity. Do the items assess the intended antecedent 
by showing expected correlation patters with other constructs?
 ► Assess concurrent validity. Do the 5C+ antecedents meaningfully relate 
to vaccination behaviour and intentions?
 ► Does adding the new antecedents improve the amount of variance 
explained by the scale?
Items of the validation constructs, translation table
Data analysis, selection of items and finalising the scale. Data legend
Syntax for data analysis
Phase 3. Data collection for monitoring or interventions (beyond this 
study protocol)
  
For monitoring, use the general version of the validated scale in a 
representative sample (eg, “I am completely confident that vaccines are 
safe.”)
–
For interventions, use the vaccine- specific version of the validated scale in 
a predetermined target group (eg, for a campaign on influenza vaccination 
targeting the elderly, assess confidence in a 60+-year- old sample with 
specific phrasing, such as “I am completely confident that the influenza 
vaccine is safe.”).
–
We share materials, a data legend and the syntax for data analysis to support the process described in this protocol via the OSF, a ‘free and 
open- source project management repository that supports researchers across their entire project life cycle’ (cited from the website9). Visit 
https://osf.io/2agxe/ to access the mentioned documents that support the process.
*In naming the resulting scale, we suggest adding the country in which it was validated in parentheses (eg, 5C (DE) or 5C (US)) and a ‘+’ sign 
when an antecedent is added (eg, the data from Nigeria suggest adding compatibility with religious beliefs, so the resulting version would be 
‘5C+(NG)’).
5C, scale to assess five psychological antecedents of vaccination; 5C+(COUNTRY), extended scale to assess more than five psychological 
antecedents of vaccination, translated in the language of a certain country (given in parentheses); OSF, Open Science Framework.
items were added as well as when existing items were 
translated. This pretesting involves distributing the ques-
tionnaire to a small sample comprising 5–10 participants 
of the target group and conducting brief cognitive inter-
views with them to obtain their feedback on the ques-
tionnaire (for sample instructions, visit https:// osf. io/ 
2agxe/). As a result of these cognitive interviews, the 
items may be adjusted to be easy to understand, unambig-
uous and without jargon.11 13 The resulting items should 
then be subjected to the procedure described in phase 2.
Phase 2: validation of the translated 5C scale
Phase 2 aims at validating the translated 5C scale and 
the potentially added new items and antecedents. The 
objective of this phase is to assess the reliability, as well 
as the construct and the concurrent validity of each 5C 
antecedent. The outcome of phase 2 will be a translated, 
adapted and validated scale. In naming the resulting scale, 
we suggest adding the country in which it was validated 
in parentheses (eg, 5C (DE) or 5C (US)) and a ‘+’ sign 
when an antecedent is added (eg, the data from Nigeria 
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suggest adding compatibility with religious beliefs, so the 
resulting version would be ‘5C+ (NG)’).
Participants
Validation entails conducting a survey involving a hetero-
geneous convenience sample with a broad range of 
demographic characteristics and assumed vaccination 
behaviours.13 Note that it is unnecessary to use a repre-
sentative sample for validation since the study focuses on 
the correlations between 5C antecedents and validation 
constructs, not on the distribution of the 5C anteced-
ents in a population. However, it is not advisable to use a 
convenience sample from a student population because 
of its homogeneity in education. Instead, it is sufficient to 
use a convenience sample from the general population.
Sample size
The recommendations about the sample sizes for valida-
tion studies vary widely.12 Given that the assessment of 
validity is based on the inspection of correlation patterns, 
we suggest using a sample comprising at least 300 partic-
ipants, which will allow detecting small correlations 
(r=0.2) with at least 95% power.14
Measures
The participants will provide their demographic 
data, answer the items of the translated (and poten-
tially extended) 5C scale, the validation constructs (to 
assess construct validity), as well as additional outcome 
measures, such as the intention to vaccinate and the 
vaccination behaviour (to assess concurrent validity).
5C
The instruction for the 5C scale are as follows: “Please 
evaluate how much you disagree or agree with the 
following statements.” (1=strongly disagree, 2=moderately 
disagree, 3=slightly disagree, 4=neutral (or: neither disagree nor 
agree), 5=slightly agree, 6=moderately agree, 7=strongly agree). 
It is advisable to keep these answer options in future 
studies. However, in telephone surveys or face- to- face 
settings, using a 5- point (1=strongly disagree, 2=somewhat 
disagree, 3=neutral (or: neither disagree nor agree), 4=somewhat 
agree, 5=strongly agree) or a 3- point scale could be advis-
able (1=no, 2=undecided, 3=yes) to reduce complexity and 
errors. Current research in Ghana has revealed that in 
some settings using Likert- type anserwing formats (eg, 1 
= I totally agree, 7 = I totally disagree) may be a challenge 
for the participants.15 Changing to other formats (eg, 
1=no, 2=undecided, 3=yes) seems advisable to reduce error 
variance. For the scoring, calculate a mean score across 
items per antecedent. Each item with (R) in table 1 is 
reverse- coded. If desired, a don’t know answer option can 
be provided additionally to the answer options. In that 
case, note that these should not be used alternatively to 
the undecided option but need to be analysed separately, 
and they can serve as an indicator of whether there was 
a challenge with the question (high percentages of don’t 
know answers could indicate that the issue is not relevant 
or the wording of the question is not suitable).
Construct validity
Appropriate validation constructs should be selected. 
As stated, table 2 provides an overview of recommended 
measures, their respective definitions and one sample 
item (for a full list of the items, visit https:// osf. io/ 
2agxe/). The validation constructs have been justified 
and used in the development of the scale.2 All items need 
to be translated into the language in which a study will 
be conducted. This is crucial because stating the items in 
a different language (eg, English in a German- speaking 
sample) will lead to error variance due to a lack of under-
standing. We also recommend applying the translation/
back- translation process described in phase 1 to ensure 
that the meaning of each item will be captured appro-
priately. Researchers should also check whether there 
are available validated scales in the local language that 
assess the same validation constructs. If this is the case, 
the scales validated in the specific language should be 
preferred. The English version of a potential question-
naire to facilitate translation is provided in the http:// 
osf. io/ 2agxe/ repository.
Concurrent validity
This part of the analysis provides the first insight into what 
the newly translated scale can predict. Table 4 provides 
an overview of potential measures with their respective 
sources to assess concurrent validity. It comprises previous 
vaccination behaviour (as this has been shown to be a 
powerful predictor of future behaviour16), future vaccina-
tion intentions (as intentions predict behaviour17), and 
the timeliness and the completeness of the vaccination 
status (as these are objective criteria for following the 
recommended schedule). We suggest assessing previous 
vaccination behaviour for several recommended vacci-
nations, which will allow both separate and combined 
analyses. Additionally, the future intention to vaccinate 
should be assessed as it provides an estimate of the scale’s 
predictive validity. Timeliness and completeness are more 
objective measures; note, however, that they will require 
more resources and may raise data protection issues (eg, 
entering data from the vaccination card, linking a patient 
to a doctor’s registry). No work has correlated all possible 
measures, so the correlation between the constructs is 
not known yet. Future work should strive for assessing all 
recommended measures to explore correlations between 
them.
Procedure
The questionnaire comprising all items described in the 
Measures section can be administered online, as a tele-
phone survey (computer- assisted telephone interview 
(CATI)) or as a face- to- face survey (paper–pencil or 
computer- assisted personal interview). Informed consent 
forms must and demographic information should be 
collected first, then the participants will fill in the 5C+ 
items, followed by the validation constructs and the 
constructs for the concurrent validity. In each scale, the 
items should be presented in a randomised order (online 
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Table 4 Constructs suitable for the assessment of concurrent validity
Construct For adult/adolescence vaccines For childhood vaccines
Intention to vaccinate 
(can ask for a specific 
vaccine X)
“Imagine that your next vaccination/X 
is due at your next routine visit to your 
general practitioner (GP). How would 
you decide?” (from 1=definitely not 
be vaccinated to 7=definitely be 
vaccinated).2
“Imagine that your oldest child’s next vaccination/X is due at 
his/her next routine visit to the GP. How would you decide?” 
(from 1=definitely not have my child vaccinated to 7=definitely 
have my child vaccinated).2
“I would like to take my preschool child for X” (from −3=strongly 
disagree to 3=strongly agree).
“How likely is it that you will take your preschool child for X?”
(from −3=very unlikely to 3=very likely); average of both 
variables.29
“How likely I am to get my child any future recommended 
vaccines (not at all likely/ very likely).” “If I had another child 
now, I would get him/her (no recommended vaccines/all 
recommended vaccines).”; average of both variables.30
Previous vaccination 
behaviour
Sum of all vaccines or 
single vaccines2 31 32
“Have you received at least one dose 
of the following vaccines?” (coded 
as 1=yes, 0=no, missing value=don’t 
know).
“Has your oldest child received at least one dose of the 
following vaccines?” (coded as 1=yes, 0=no and missing 
value=don’t know).
Completeness of 
vaccination status2 
31–33
Number of doses received relative to 
the total number of recommended 
doses.
A copy of the vaccination card or 
the provider- recorded data can be 
retrieved to obtain objective data.
  
Timeliness of 
vaccination34–36
  Age in days (and reported as whole months) when a child being 
administered each vaccine dose is calculated by subtracting 
his/her date of birth from the vaccination date. This age in days 
is compared with the recommended age ranges based on the 
official vaccination card.
The measurement details are provided in their respective references.
survey or CATI); alternatively, several versions with 
different orders of the items should be created before 
printing (paper- and- pencil version for a face- to- face 
survey).
Data analysis
A syntax, along with the data legend provided at https:// 
osf. io/ 2agxe/, can assist researchers in conducting 
the following steps. Note that when using the provided 
syntax, the variable names should match the names in the 
data legend.
Reliability
For each 5C antecedent and validation construct, Cron-
bach’s alpha should be calculated to assess the scale’s 
internal consistency (ie, the extent to which a set of 
items measures the same construct). Before calcu-
lating Cronbach’s alpha, reverse- coded items need to 
be recoded (cf. the syntax at https:// osf. io/ 2agxe/). 
The Cronbach’s alpha value should be above 0.7013 for 
each 5C antecedent. Assuming that α ≥0.70, the mean 
values are calculated per antecedent. Sensitivity analysis 
is conducted by using the ‘if item deleted’ procedure; 
for each 5C antecedent, Cronbach’s alpha is assessed as 
it would occur without each of the items. This indicates 
which item could be eliminated if the Cronbach’s alpha 
value is too low. Moreover, it should be ensured that the 
item- total correlation is sufficient. This process should 
also be applied when there are additional items to adapt 
the scale to the cultural or the epidemiological context 
(eg, ‘The way in which vaccines are offered keeps me 
from being vaccinated’ as a potential additional item for 
constraints). The items that lead to the highest internal 
consistency should be selected even if it means dropping 
original items from the scale or resulting in a version that 
has more or less than three items. We suggest, however, 
to strive for three items per antecedent. When high reli-
ability is assured, the next step should assess whether the 
translated (and potentially changed) antecedents still 
possesses construct validity.
Construct validity
To assess construct validity, Pearson’s correlations are 
calculated between the 5C antecedents (eg, confidence) 
and their respective validation constructs (eg, attitude, 
knowledge, trust in healthcare providers). The set of 
correlations indicated in table 2 is obtained from the 
development process2 and serves as a benchmark. The 
validation study’s results should be similar to the original 
correlations. If one or several of the correlations turn out 
to be substantially lower (eg, 0.10 instead of 0.30), this 
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can indicate that either the 5C antecedents or the vali-
dation constructs lack reliability. In either case, double 
check whether all constructs have sufficient reliability 
and consider eliminating items that decrease the reli-
ability by performing the previously described ‘if item 
deleted’ procedure. Moreover, it is possible that the trans-
lation process has changed parts of the meaning of the 
constructs. In this case, double- check the translations of 
the specific constructs. It could also be that in a specific 
country, not all antecedents are correlated with their 
respective validation constructs (eg, confidence is related 
to a positive attitude toward vaccination but not to trust 
in authorities). The interpretation of the pattern of the 
results should consider these aspects.
Validation of new 5C antecedents (5C+)
When the 5C scale has been extended (5C+), the same 
procedure, as described for reliability and construct 
validity, should be applied to the new antecedent(s). For 
example, regarding compatibility with religious beliefs, a 
research team might have selected religiosity as a valida-
tion construct, for example measured by the Centrality 
of Religion Scale.18 A potential hypothesis could be that 
there would be a positive correlation between compati-
bility with religious beliefs and centrality of religion, as 
someone who is less religious may not care whether vacci-
nation is compatible with his/her religious beliefs.
Concurrent validity
The next step assesses whether the 5C antecedents 
predict the intention to vaccinate, as well as previous 
vaccination behaviour(s) or any of the other constructs 
suggested in table 4. For each dependent variable, a 
stepwise regression analysis is conducted (eg, logistic 
regressions predicting having versus not having been 
administered a specific vaccine by using the 5C+ anteced-
ents, or linear regressions predicting the sum of the 
administered vaccines). The demographics are added as 
predictors in the first step, and all original 5C anteced-
ents are included in the second step. If the scale has been 
extended (5C+), the new antecedent(s) is (are) added 
in the third step. Increases in R2 (coefficient of determi-
nation indicating the percentage of explained variance) 
should be compared in each step. It should be explored 
whether the extended version (5C+) consistently (ie, 
across several dependent variables) explains significantly 
more variance than the original 5C scale does. If so, the 
extension should be used in further work. Otherwise, 
the original version is sufficient and should be used for 
economic reasons.
Selecting items for a short scale
To develop a short scale, one item should be selected to 
represent each antecedent. To determine which item 
is best suited, the mean of the three items assessing 
one antecedent, as well as each of these three items, is 
correlated with the validation constructs. The item that 
correlates most similarly with the validation construct 
compared with the three- item mean should be selected 
(expected direction, to a similar extent).2
Patient and public involvement
Members of the target group can be involved in phase 1 
in the expert evaluation phase (eg, in focus groups with 
parents to explore potential further antecedents) and as 
participants providing feedback in the pretest phase. In 
phase 2, there is no further public and patient involve-
ment other than recruiting participants from the public 
to assess their psychological antecedents of vaccination.
EthICs And dIssEMInAtIon
The University of Erfurt’s institutional review board 
provided ethical clearance (EV-201900416.2). All partic-
ipants who will take part in the study will provide their 
written informed consent to use and share their data 
for scientific purposes without disclosure of their iden-
tity. Analyses and data storing use anonymised data and 
cannot identify individual participants.
The authors suggest and encourage publicly sharing 
all data obtained from the translated 5C scale used (eg, 
on publication). Sharing data on vaccine acceptance and 
demand is in the public and the scientific interest and 
will facilitate gaining a global overview of its current state 
and development over time. The authors of the original 
5C scale are currently working on an online platform to 
visualise the psychological antecedents across different 
countries.
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